SOURCE: Protherics PLC

November 26, 2007 12:29 ET

Protherics PLC announces Director/PDMR Shareholding - 2

Cheshire, UK--(Marketwire - November 26, 2007) -

                                 Protherics PLC

                         Notification of PDMR Interests

London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC ("Protherics"
or the "Company"), the international biopharmaceutical company focused on
critical care and cancer, announces that, on 23 November 2007, the following
options over ordinary shares of 2 pence each in Protherics ("Ordinary Shares")
were granted under the terms of the Company's Long Term Incentive Plan:

Name                Position                                    Number of

Ian Scoular         Director of Business Development              148,837
Nicholas Staples    Director of Corporate Affairs                 125,581
Sally Waterman      Director of Research & Development            148,837

The options are exercisable at a price of 2 pence per share between the third
and tenth anniversary of the date of grant, subject to the achievement of
performance conditions.

Following the above grant, the total number of options held are as follows:

Ian Scoular                               1,121,731
Nick Staples                                674,744
Sally Waterman                              809,210

The current issued ordinary share capital of the Company is 339,696,822 shares.

For further information please contact:

Nick Staples, Director of Corporate Affairs                +44 (0) 7919  480510
Julie Vickers, Company Secretary                           +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott                              +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt                    +1 212 850 5600

Or visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange